Background: Benign prostatic hyperplasia (BPH) is the most common urological disease
secretion by CD8 + T cells by downregulating nuclear factor-κB p65 phosphorylation, which reduced the growth of BPH-1 through CCL5/STAT5/CCND1 signaling.
Conclusions:
Our results indicate that the upregulation of the cGMP/PKG/p65 signaling reduces CCL5 secretion in CD8 + T cells, which in turn decreases the proliferation of BECs in low androgen conditions, suggesting that the combination of 5α reductase inhibitors lowering androgen levels and PDE5-Is may be a novel, more effective treatment for BPH patients.
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| INTRODUCTION
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are common in the aging male population and their prevalence is increasing; however, the pathophysiological mechanisms underlying BPH development are complex and poorly understood. Score, storage and voiding LUTS, and improve quality of life. [2] [3] [4] [5] Most studies suggested that the clinical effect of PDE5-Is is associated with cyclic guanosine monophosphate (cGMP) signaling through cGMPdependent protein kinase G (PKG), which mainly reduces smooth muscle tone of the detrusor, prostate, and urethra, thus relieving LUTS. [6] [7] [8] Dihydrotestosterone synthesized from testosterone by 5α-reductase (5AR) II plays a critical role in prostate growth, and a 5AR inhibitor (5AR-I) finasteride is known to alleviate BPH symptoms. In our previous studies, we have shown that BPH tissues from finasteride-treated patients had increased CD8 + T-cell infiltration, 9 which could promote the proliferation of BPH epithelial cells (BECs) in low androgen conditions by secreting a chemokine CCL5
(also known as RANTES). 10 Moreover, we also found that PDE5
protein expression positively correlated with CD8 + T-cell infiltration and CCL5 and cyclin D1 levels in human BPH tissues, whereas activation of cGMP/PKG signaling could suppress CD8 + T-cell infiltration and the expression of CCL5 and cyclin D1 in preliminary experiments using a high-fat diet (HFD) BPH rat model. Other studies have also reported that the cGMP/PKG signaling pathway may regulate the inflammatory response implicated in several pathological conditions, including BPH, [11] [12] [13] but the mechanism of cGMP/PKG signaling and its specific role in inflammation in the prostate is not well understood. In particular, activation of the cGMP/PKG pathway in CD8 + T cells and its effect on BEC proliferation is unclear, and there are few reports on the relationship between the cGMP/PKG pathway and CCL5 secretion. Therefore, the aim of the present study was to clarify the involvement of the cGMP/PKG pathway in the regulation of CCL5 expression in CD8 + T cells and its effect on BEC proliferation in low androgen conditions.
| MATERIALS AND METHODS

| Patients
Patients were selected using the electronic medical record system containing the data on 921 patients with BPH who underwent 
| Animals
An HFD-induced prostatic hyperplasia model was established as previously described. [14] [15] [16] Male Sprague-Dawley rats (7-to 9-week old;
200-220 g) (Beijing Keao Xieli Feed Co, Ltd, Beijing, China) were housed in individual cages under standard conditions in a temperature-and humidity-controlled room with a 12-hour light/dark cycle and had free access to food and water. After a week on a standard rat diet, animals were randomly assigned to control (n = 6), HFD (n = 6) or HFD + PDE5-Is (n = 6) groups according to their weight. 
| Reagents and antibodies
The following antibodies were used for immunohistochemistry (IHC) and 
| Immunohistochemistry
Serial paraffin sections of the prostate samples were stained with specific antibodies using IHC as previously described. 10 Quantitative analysis was performed by measuring integrated optical density using the Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD).
The degree of prostatic CD8 + T-cell infiltration was calculated as the mean number of CD8 + T-cell aggregates in the prostate stroma observed under ×100 objective (CX31, Olympus Corporation, Tokyo, Japan). The expression intensity of CCL5, CCND1, and PDE5 protein was assessed semiquantitatively as integrated optical density under ×100 objective (Olympus Microscope). Each prostate sample was selected by five horizons. All analyses were performed by two experienced pathologists in a blinded fashion. 
| Cell lines and coculture experiments
BPH-1 and Molt-3 cells were incubated for 3 days and collected for
Western blot analysis performed as described previously. | 911
| Statistical analysis
The data are expressed as the mean ± SD of at least three independent experiments. Differences between groups were analyzed by a paired t test. IHC data were analyzed by linear regression correlation or analysis of variance (ANOVA). P < 0.05 were considered as statistically significant. All statistical analyses were performed using SPSS 17.0 (SPSS Inc, Chicago, IL).
3 | RESULTS
| Infiltration of CD8 + T cells and expression of CCL5, CCND1, and PDE5 in human BPH prostate samples
Our previous studies have shown that induction of CCL5 secretion by infiltrating CD8 + T cells promoted BEC proliferation in low androgen conditions. 10 In the present study, we examined the infiltration of . β-Tubulin and GAPDH were used as loading controls. BEC, BPH epithelial cell; BPH, benign prostatic hyperplasia; cGMP, cyclic guanosine monophosphate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NF-κB, nuclear factor-κB; PKG, protein kinase G; STAT5, signal transducer and activator of transcription 5; TDF, tadalafil F I G U R E 2 Activation of the cGMP/PKG signaling pathway could reverse the induction of BEC proliferation by CD8 + T cells through suppressing the secretion of CCL5 by CD8 + T cells in low androgen conditions. BECs were cocultured with or without Molt-3 cells in low androgen conditions for 4 days. A,C, BECs cultured with rhCCL5 (1 μg/mL) and tadalafil (100 nM) or Sp-8-Br-PET-cGMP (10 μM) were analyzed for proliferation at days 2, 4, and 6 using the CCK-8 assay. The data are shown as the mean ± SD; *P < 0.05 and **P < 0.01. B,D, BECs were harvested at day 4 and analyzed for CCND1 expression by Western blot analysis; β-Tubulin was used as a loading control. E-G, CCL5 mRNA expression in Molt-3 cells at day 2 was analyzed by qPCR. CCL5 mRNA levels were downregulated by tadalafil (100 nM) or Sp-8-Br-PET-cGMP (10 μM) in Molt-3 cells cocultured with BECs, but KT5823 (100 nM) reversed the effect. H, CCL5 secretion to conditioned medium of cocultures and monocultures treated or not with tadalafil and/or KT5823 at day 4 was assessed by ELISA. I,J, BPH-1 cells treated or not with tadalafil or Sp-8-Br-PET-cGMP, anti-CCL5 neutralizing antibody (2 μg/mL), and KT5823 were analyzed for proliferation at days 2, 4, and 6 using the CCK-8 assay. Data are shown as the mean ± SD; *P < 0.05 and **P < 0.01. BEC, BPH epithelial cell; BPH, benign prostatic hyperplasia; CCK-8, cell counting kit-8; cGMP, cyclic guanosine monophosphate; ELISA, enzyme-linked immunosorbent assay; mRNA, messenger RNA; PKG, protein kinase G; qPCR, quantitative polymerase chain reaction, TDF, tadalafil [Color figure can be viewed at wileyonlinelibrary.com] associated with PDE5-Is is considered to relax smooth muscle in the prostate. 6 Moreover, Vignozzi et al 11, 14 found that PDE5-Is could inhibit inflammation levels in overall prostate, and we also A, The degree of prostatic hyperplasia in rats receiving regular diet (RD), HFD, or HFD + PDE5-Is was evaluated by hematoxylin and eosin staining of rat prostate samples (n = 6 rats per group). B, The serum testosterone levels of RD and HFD groups were measured using an automated chemiluminescence system at week 12; *P < 0.05, **P < 0.01, and ***P < 0.001 (by t test). C, All rat prostate weight of three groups were tested at last; *P < 0.05, **P < 0.01, and ***P < 0.001 (by one-way ANOVA [21] [22] [23] and that cGMP/PKG activation inhibited NF-κB in hyperthermia-exposed MCF-7 cells, resulting in apoptosis. 21 In this study, we showed, for the first However, some limitations of this study should be recognized.
The major one is the deficiency of clinical BPH samples which were treated with both 5AR-Is and PDE5-Is. In addition, CD8 + T cells in rat prostate tissues were not separated by fluorescence-activated cell sorting to further certify the function of the cGMP/PKG pathway.
| CONCLUSIONS
The important finding of the present study is that the activation of the cGMP/PKG/p65 pathway associated with PDE5-Is in CD8 + T cells under low androgen conditions reduces the secretion of CCL5, which results in the inhibition of BEC proliferation via CCL5/STAT5/ CCND1 signaling ( Figure 5 ). As PDE-Is block CCL5 secretion by CD8 + T cells and 5AR-Is the reduce androgen levels, the combination of these drugs may effectively suppress the growth of BECs in the prostate, and therefore, can be considered as a candidate therapeutic approach for BPH patients in the future.
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